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Summary 
  The size of medical device industry has been about 360 billion dollars and it is one of the huge 
growth markets. Although Japan has the world's second largest market, Japanese companies are not 
ranked as one of the top ten medical device sections. Under such circumstances, keen attention has 
been to one of the human resource development programs, "Biodesign" at Stanford University.  
 The purpose of this paper is to quantitatively analyze the impact of "Biodesign" program on startup 
companies in the United States and to consider issues about how to introduce the program into Japan. 
In the analysis of this paper, the “Crunchbase” database was used to obtain medical device startup 
companies founded in California, and statistically compared the management performance of 
companies founded after the "Biodesign" Program and that of other companies. Some performance 
measure such as initial funding amount, period until initial funding, and total amount of funding for 5 
years from establishment could be regarded as success factors.  
 As a result of quantitative analysis of the Biodesign, we find that the companies established through 
Biodesign showed similar results in terms of short-term funding compared with other medical device 
startups. However, in terms of medium-term funding, Biodesign firms statistically showed negative 
significant performance. The companies founded through Biodesign with Ph.D. and M.D., however, 
showed a significantly positive significantly performance in terms of medium-term funding. We 
therefore may imply that Biodesign might be good at leveraging human resources with professional 
abilities like Ph.D., M.D., which may have improved corporate performance. 
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CHAPTER1． INTRODUCTION 
 
 The market size of medical device industry is said to be about 360 billion dollars 
and it is one of the huge growth markets. Although Japan has the world's second 
largest market size in this industrial field, Japanese companies are not ranked as one 
of the top ten medical device manufacturers rankings. In the domestic medical device 
industry, new product development with its own resources is no longer at its limits 
due to cost increase due to international competition, needs complication due to 
evolution of medical technology, necessity of medical engineering collaboration, 
uncertainty of innovation, and so on. Henry Chesbrough stated that in order to create 
innovation, companies should not rely solely on internal resources, but that 
cooperation with other companies, including academia and start-up companies, is 
indispensable. 【Chesbrough, 2003】  In fact, many big medical device companies in 
the United States have taken the strategy of leaving new product development, 
innovation, to start-up companies. The large company develops the technology by 
investing regularly in the startup company, and acquires it at an appropriate time. A 
business ecosystem such as represented by Silicon Valley supports such a medical 
device industry in the United States. In Japan, it is an urgent issue that the 
establishing the medical business ecosystem similar to the United States. The most 
important matter in constructing the business ecosystem is recognized as 
improvement of environment where startup companies are born one after another 
and the creation of a talent pool in which experienced entrepreneurs support the next 
entrepreneur. However, at present, there are few entrepreneurs, and even if they 
challenge boldly, support by the market environment is poor. Moreover, they are not 
succeeded in creating innovation as expected because they are blocked by "Devil 
River", "Valley of Death”, and "Darwinian Sea". 
 Under such circumstances, attention is being paid by the domestic medical device 
industry is the human resource development program "Biodesign" from Stanford 
University. Biodesign is an educational program that brings teams with excellent 
talent to diversity, extracts clinical needs from medical sites, and supports 
commercialization of solutions, and has made significant achievements in the United 
States. Therefore, in recent years, by introducing this program in Japan, it is expected 
to contribute to the construction of business ecosystem in the domestic medical 
device industry. 
 However, research on the outcome of Biodesign in the United States is still limited 
and not enough. In particular, there are few studies to clarify the mechanisms such as 
why results (eg innovation creation) were obtained by Biodesign. Japan has the 
purpose of introducing Biodesign under a different environment from the United 
States and building a business ecosystem of the medical device industry. In this 
situation, trusting the outcome of the program blindly was should be avoided. In 
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order to introduce the program in Japan, the essence of the mechanism must be 
understood and problems should be extracted, otherwise achievement of goals will 
doubted. 
  Therefore, in this research, focusing on the management performance at the 
beginning of the business ecosystem of the company established through the 
Stanford Biodesign Program, quantitative analysis was carried out using the success 
factors. This will give new insights on what characteristics of Biodesign strongly 
influence innovation. Also from this result, issues and prospects will be considered 
for building the business ecosystem with this program in the domestic medical 
device industry.  This paper consists of 5 chapters. In chapter 2, after describing the survey results 
on the current situation in the medical device industry, describe the details of the 
business ecosystem that is required in the relevant industry. In addition, the 
relationship between the financing process of the start-up company, which is 
indispensable for talking about this business ecosystem and the enhancement of 
corporate value is described. Next, in chapter 3, I will touch on the outline and past 
achievements of the Stanford Biodesign Program. In chapter 4, for the hypothesis 
"Companies founded after Biodesign show high management performance from 
other medical device startup companies", The amount of initial funds raised, the total 
amount of funds procured in the medium term, etc. were set as the growth indicators 
of the company, and the influence of these companies on the Biodesign Program was 
quantitatively analyzed. Quantitative analysis was also conducted on the influence of 
human resources composition at the time of establishment on the above success 
indicators, and the features and merits and demerits of the Biodesign Program were 
discussed. In Chapter 5, this paper was overhauled, the mechanisms and issues of the 
Stanford Biodesign Program were discussed, and issues on introduction to the 
medical device industry in Japan were examined.  
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CHAPTER2． BACKGROUND OF THIS STUDY  
 
SECTION1. THE MEDICAL DEVISES INDUSTRY 
1. The medical device industry in the world 
 In recent years, the medical device industry in the world has received a great 
deal of attention. The market is estimated to be about 360 billion dollars as of 
2015.【Kalorama Information、2015】Looking at the breakdown by country in the 
market, it is calculated that the United States accounts for 40%, the EU about 10 
to 15%, and Japan is 10%, accounting for about 65% in these three regions. The 
market in the EU as a whole is larger than Japan, but in a single country, the half 
of the world market is constituted in Japan and the United States. The medical 
device market is projected to grow at about 8% annually in the market as a whole, 
and it is expected to exceed 470 billion dollars in 2020. There are several factors 
that contribute to stable expansion of medical markets. The biggest factor is the 
aging of the people. The total population of the world in 2015 is 7,344,947 
thousand people and is estimated to be 10,142,900 thousand people in 2060. The 
proportion of people aged 65 years or over (aged population) in the total 
population rose from 5.1% in 1950 to 8.3% in 2015, but it further rises to 18.1% in 
2060, which means that the aging will progress rapidly in the latter half of the 
century. Looking at future estimates of the aging rate by region, it is expected 
that aging will progress rapidly not only in developed regions, but also in 
developing regions. 【Ministry of Health, Labor and Welfare, 2017】With the rise 
in the proportion of the elderly, medical needs for the elderly are expected to 
rise sharply. However, in this market fluctuation, remarkable growth of key 
Asian countries such as China and India will occur, and competition of the 
medical device market will be intensified worldwide. And as a result, market 
share is expected to decline in Japan. 
2. The medical device industry in the United States 
 From the breakdown by country in the medical device industry worldwide, it 
is clear that the United States has overwhelming presence. The medical device 
market in the United States is the world's largest producer and consuming 
country, so companies from all over the world are entering. Approximately 6,500 
companies exist in the medical device industry in the United States, direct 
employment will be 350,000 and indirect employers will be 2 million. However, 
80% of these companies are small and medium enterprises with less than 50 
employees, which is one of the characteristics of the US medical device industry. 
Entrepreneurial culture has also penetrated, and many companies operate only 
investment funds without sales, so it can be said that the market is expected 
from the financial market. Analysis of the market breakdown of US medical 
device shows that there is a big difference for each medical field. Of the 
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approximately 140 billion dollars in the current medical device market in the 
United States, about 30% are in the cardiovascular field, about 20% in the 
orthopedic field, general surgery field, ophthalmologic field and wound care 
field each about 10%. The biggest area of US medical device sales is orthopedic 
surgery, followed by general surgical instruments and diagnostic equipment.   
 As mentioned above, the aging of the population is one of the factors 
supporting the growth of the medical device industry, which is no exception in 
the United States. As of 2015, the population aged 65 and over accounts for 
14.9% of the total population, and it is expected that the aging will be improved. 
Even if the number of deaths and number of overseas movements is deducted, 4 
million people per year, that is, 10,000 a day reach 65 years of age. According to 
the US census, the elderly population aged 65 and older is expected to expand 
from 43.15 million in 2012 (13.7% of the population) to 83.74 million (20.9% of 
the population) in 2050.【United States Census Bureau, United States Department 
of Commerce, 2012】The proportion of the elderly people is still lower than Japan 
(26.6%), but it is 2030 that the population of the last baby boomer generation 
reaches 65 years old, the elderly population is expected to rise more and more; it 
is thought that medical needs for people will increase rapidly. 【Statistic Bureau, 
Ministry of Internal Affairs and Communications, 2015】  
3. The medical device industry in Japan 
  The medical device market in Japan accounts for 10% of the world market, it is 
the second largest market after the United States which accounts for about 40% 
of the world market, and since 1995 it has gradually expanded at an annual rate 
of 2.3%. The market of the medical device in Japan turned to increase after 2004, 
reaching a record high of about 2.8 trillion yen in 2014, and it is still growing 
now. Looking at the breakdown of the domestic market in 2014, 53% (1410.3 
billion yen) of therapeutic equipment (Catheter, pacemaker, etc.), 26% (696.3 
billion yen) of diagnostic equipment (endoscope, CT, MRI etc.) and 21% (569.1 
billion yen) of others (dental materials, ophthalmic materials, etc.) account for 
amounts on a value basis.【Ministry of Economy, Trade and Industry, 2015】  
Growth rate in each area is 3.8%, 2.0%, 1.0%, and generally it can be seen that 
both the market size and the growth rate of the therapeutic equipment are high.   
  However, it is also known that the import ratio of therapeutic equipment is 
relatively high. Looking at the trend of import and export of the domestic 
medical device market, the import amount is also increasing with the market 
scale increase since 2004. On the other hand, although the export value is on an 
upward trend, the increase in the import value is higher than the export value, 
therefore the excess import amount tends to increase. For example, 100% of 
artificial heart valves and cardiac pacemakers are imported products, the import 
ratio of therapeutic medical device with large market size exceeds 50%, and the 
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trade balance of medical device in Japan is in deficit. Looking at the world 
ranking of medical device makers, only two Japanese companies are in 30 
companies 【 Medical Product Outsourcing, 2016 】 , and international 
competitiveness in world markets is low except for some diagnostic equipment. 
Industry support by the government has also begun, as it is a rare field among 
Japanese industries, which is mainly exported in many fields such as 
automobiles and home appliances. 
 
 
 
 
 
SECTION2. BUSINESS ECOSYSTEM IN MEDICAL DEVICE INDUSTRY 
 Since the quality of the medical device is directly linked to the life of the patient, 
development and manufacture which combines precision and accuracy is 
indispensable industries. Originally, such an area should be a specialty of Japan, but 
it is very disappointing that it is an excess of imports. One of the reasons for making 
such a situation is that there are few startup companies in Japan.  
 A startup company means that their goal is to change the world through creation of 
innovation that has never existed, with initial public offering (IPO) or acquisition by 
a major company (M&A).【Brandon K. Hill, 2013】 In the case of major companies, 
even if they have high technology, development speed cannot be raised quite easily 
due to factors called "The Innovator's Dilemma" such as stiffening of organization, 
avoidance of cannibalization, and the lack of leadership when developing products 
Figure. Top 30 medical device manufacturers in 2016.  
Source: Medical Product Outsourcing 
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not yet exist in the world.【Clayton Christensen, 1997】However, because there is 
nothing to be lost by startup companies due to failure, it is possible to promote 
development promptly. As a major company, acquiring a start-up company that 
developed a new product, compared with developing it themselves, can reduce risk 
and time. As a matter of fact, new medical instruments of large foreign-capital 
companies dealing with therapeutic equipment are often developed by start-up 
companies. The fact that there are many startup companies that large companies 
want to acquire in abroad and there are only a few in Japan.  Therefore, it declines 
the development capability of Japanese company, and it leads a excess of import. 
 In order for the startup companies to succeed one after another in Japan, it will be 
necessary to make the business ecosystem as established in Silicon Valley, Minnesota, 
Israel etc., adapting to the Japanese trend. The business ecosystem refers to the 
human flow which is starting from creation of ideas, to establishing start-up 
companies, product development, launch, EXIT (IPO, M&A), creating new ideas and 
establishing the next start-up company after EXIT. According to Moore, James F., 
which was first proposed, there is an explanation "An economic community 
supported by a foundation of interacting organizations and individuals-the 
organisms of the business world." 
【Moore, James F, 1993】The features of the business ecosystem of the medical device 
startup company will be described below from the aspect of human resources 
required at each stage 
 Figure. Business ecosystem in medical device industry 
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1. Idea creation 
  Like other industries, ideas are necessary to create innovation by startup 
companies even in the medical device industry. And what is important here is 
the presence of medical staff. In the field of medical device, good product ideas 
are often devised from the clinical needs of medical sites, so ideas by medical 
staff who actually use medical device are indispensable for innovation. On the 
contrary, if a researcher of a company, not a healthcare worker, takes a method to 
find an adaptable medical problem after inventing a new technology, it is more 
likely to fail. For products that aim to apply new technology, even if the 
technology is innovative, it is a product that only top-notch doctors can handle, 
or does not accurately catch the needs of the site. This situation does not bring 
any great success of business in the industry.  
2. Business design 
  In this phase, human resources who are familiar with medical device business 
are necessary as well as medicine and engineering, and their commercialization 
study is necessary. As a concept of commercialization, the final objective of EXIT 
(IPO, M&A) should be considered at first, then consider the market, Regulatory 
requirements, clinical trials, patents, funds, time, human resources by 
calculating backwards. Failure is likely to occur when promoting without 
drawing the image of the final goal. Time and funds are spent only to realize 
needs solving means, and it is likely that the examination task for market 
selection to be postponed such as “who the customer is” and “how big the 
market is about”. Especially, in the case of a start-up company, since funds and 
time investing in product development are limited, it is necessary to promote 
development focusing on one particular market. Basically it is impossible to 
develop multiple products at the same time or target multiple markets at the 
same time. Therefore, market should be carefully selected. For this stage, 
forecast of corporate value at the time of EXIT should also be considered. 
Otherwise it will not be judged how much can be invested in development and 
commercialization. Without this consideration, the worst case that EXIT cannot 
be done often occurs. 
3. Product development 
  At the product development stage after commercialization design, 
development engineers, experts in patents and pharmaceutical affairs are 
important. Specific activities include patent strategy, product specification 
review, non-clinical trials, etc. When startup companies enter this stage, small 
businesses and incubators often support innovation creation.  
4. Clinical study 
  After the nonclinical study is completed, it is possible to challenge "First in 
men". In this phase, not only experts in regulatory strategies but also experts 
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with wide inter-company networks and international networks will be needed. 
This is because clinical trials need for collaboration with manufacturing and 
sales companies. Also, in Silicon Valley companies, it is rare to conduct in the 
United States, and clinical trials are often carried out in developed countries 
such as Central and South America. If the value of the product is recognized, you 
can proceed with the process of obtaining European approval by acquiring the 
CE mark or aiming for FDA approval in the United States.  
5. Manufacturing and sales 
  If you get regulatory approval, you will need to consider insurance strategies. 
Because the regulatory approval is clear at this stage, the risk to the acquiring 
company is the lowest, so M&A deals increase. Mergers and acquisitions 
negotiations require special skills as opposed to management, so specialists are 
needed. Even if you aim for IPO without being M&A, sales functions will require 
special talent those who are completely different from people in product 
development so far. Therefore, the management team of start-up companies is 
often replaced and the organizational structure is changed. 
6. After Exit 
  Start-up companies that have exit (IPO, M&A) become exceptional companies 
called large companies. If it is an IPO, it will expand our company scale 
independently. If it is M&A, it will become a member of a large company from 
that moment. As a result, talented people who are suitable for organizations in 
large companies are needed, and the talent who has worked in startup 
companies will retire. These people will become serial entrepreneurs, venture 
capitalists, angels, etc. and try to get involved in some way again to the startup 
company.  
 Such a cycle of human resources will improve the number of startup talent in the 
industry. And by building strongly the business ecosystem, an environment where 
innovation can be born continually is created. In the next section, one of the factors of 
the business ecosystem is described about the institution that supports financing for 
startup talent. 
 
SECTION3. VENTURE FINANCE 
 In the previous section, it was mentioned how the startup talent circulates in the 
business ecosystem in the medical device industry and leads to the next innovation. 
In this section, the funding method, which is essential for startup companies to 
become part of the business ecosystem, and the impact on corporate growth  are 
described. 
 Indirect finance and direct financing can be considered as methods of raising funds. 
But, direct finance is the easiest for start-up companies to choose. This is because 
there are multiple restrictions on startup companies, such as (1) the amount of assets 
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is small and the collateral capacity is limited, (2) the sales to be used for principal 
repayment and interest payment are insufficient, (3) even if there is sales, it is 
necessary to retain funds for future growth, (4) the company's reliability is low 
because it is not long before the financial institution cannot take risks. Therefore, for 
start-up companies, it is indispensable to procure risk money by direct financing 
such as investment. And how much of this risk money can be procured on a timely 
basis is the fate of the startup company's initial growth. Actually, when investigating 
the needs of startup companies, financing is often recognized as the most important 
issue.  
 
 
 
 
 
 It can be thought that there are roughly four ways to procure risk money.  These are 
often used properly according to the growth stage of startup companies.  Each 
method will be briefly described. First, one is funds to procure through personal 
connection, such as the founders' families and acquaintances, in the founding seed 
period. Next, when you enter the startup phase where ideas and business plans 
become clear, you will be able to procure funds from business angels. Angel is not 
only a loan of risk money in the early period of entrepreneurs, which is very difficult 
to raise funds, but in many cases it is a human resource who has experience of 
Figure. Financing cycle in startup ecosystem. 
Source: https://commons.wikimedia.org/wiki/File:Startup_financing_cycle.svg  
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successfully conducting his own business as mentioned above. Therefore, support 
from business experience and expertise is also expected. When entering the 
expansion phase when product development and non-clinical trials begin, venture 
capital will also be the source of funding. The venture capital can sometimes procure 
to nearly 1 billion yen depending on the size of the company, so it goes without 
saying that the future of the startup company will greatly change according to the 
funding strategy at this stage. If raising funds from venture capital and become able 
to calculate the number of customers and changes in sales to a certain extent was 
succeeded, indirect finance also comes into the choice as a source of funding.  As a 
final step, if sales and profits increase, large-scale financing through public offering 
becomes possible.  
 In this way, the start-up company is destined to continue to suffer from the 
problem of how to raise funds at each stage immediately after its founding.  In other 
words, it is no doubt that continuing to solve this problem is one way to approach 
success. According to Miyake et al., "It is clear that the success of fund procurement 
will have a positive influence on Exit grades in US bio-tech startup companies" 
【Yuya, Myake, 2010】 , although it is not a medical device industry. From this, it can 
be said that the success of financing at start-up companies affects Exit results, that is, 
it increases the number of entrepreneurs in the business ecosystem talent pool.  
 
SECTION4. RESEARCH OBJECTIVES 
 Based on the above, it can be said that the business ecosystem of the medical device 
industry constructed by Silicon Valley etc. has been established as a system to 
support society as a whole in order for a good start-up company to be born and to 
grow. To create innovation there should not only be a human resources pool and 
environment, but also some startup companies. And angels, venture capital, 
incubators, etc. support corporate financing and R&D, since it is extremely difficult 
to succeed alone after the establishment. With the growth of startup companies, 
necessary human resources are complemented each time to create innovation. Thus, 
it is a well-known fact that human circulation exists as a business ecosystem which is 
the source of innovation. Therefore, as a future task, it should be considered how to 
maintain (or expand) this system. There are two points that are considered to be 
important. 
 First of all, it is to increase the number of talent to enter the business ecosystem. 
Regarding the creation of talent pool, it is important how to make human resources 
with experience of success into the business ecosystem. On the other hand, talented 
people who gained experience in successful in business ecosystem often choose to 
return to start-up companies or belong to venture capital and support venture 
industry. But of course it is not everything. Some people continue to work at the 
company after EXIT, others are retiring. In addition, many startup companies will 
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withdraw from without success. What is important in such a market environment is 
whether to increase the number of human resources who challenge entrepreneurs for 
the first time and to make the experience of success of start-up companies. If this 
becomes possible, the talent pool of the business ecosystem will continue to increase, 
the frequency of innovation will increase, and it will be said that it will definitely 
effect to the activation of the entire medical device industry. 
 Another is to improve the quality of innovation of startup companies. Not only 
frequency, but also high quality innovation is should be created from the business 
ecosystem. Thus the success experience of the talent will be strengthened and 
reputation will attract talent to the business ecosystem. In order to improve the 
quality of innovation, the quality of the initial stage is very important.  Specifically, it 
is a high-quality idea and a technology which can embody it. If this goes well, 
financing will proceed smoothly and it will be closer to EXIT. As a matter of fact, if 
shortage of funds of start-up companies in the early stages, innovation is likely to be 
unexpectedly ended, because malfunction of the whole venture finance. 
 With respect to the above-mentioned subjects, looking at Silicon Valley medical 
device industry business ecosystem, "Biodesign" from Stanford University attracts 
attention in recent years.  It can be said that this program is one solution to the 
above problem. 
 
 
 
Figure. Relationship between diversity and quality of innovation. 
Source: https://hbr.org/2004/09/perfecting-cross-pollination 
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 First of all, from the perspective of human resources who enter the business 
ecosystem, this program is an excellent educational program and people with little 
business experience can learn innovation thoroughly under mentorship by 
professional businessmen. Many excellent young people are gathering to attend the 
program because there is a reputation that it leads to career enhancement by 
accepting education by professional businessmen. And also the possibility of failure 
of entrepreneurs declines. From the viewpoint of improving the quality of innovation, 
because this program is based on design thinking, it is a problem-solving program 
that connects medicine and engineering, covering everything from finding clinical 
needs and creating ideas to planning a commercialization plan. Since the program 
participants actually start observing at the medical field, there is a high possibility of 
discovering the latent needs. Also, since it is a program to examine entrepreneurial 
ideas by teams of talented people selected from high magnification, many 
commercialization plans are also high quality. According to Fleming Lee, "When the 
diversity of members is low, the value of innovation remains moderate, but high 
diversity of members increases high value innovation and low value innovation." 
【Fleming Lee, 2004】  The Biodesign Program is distinctive in that it gathers diverse 
and talented human resources and is fully supported by experienced mentoring 
support, creating high-value innovation is expected. 
 But here, if you mention the part that is not yet fully discussed about this program, 
it is about quantitative research on innovation. A lot of innovation has been created 
by the program participants, but the relative quantitative comparison between that 
the startup from Biodesign and the other startup in this industry has not been carried 
out. Quantitative comparisons are not made indicates, thus discussion has not been 
done  on the specificity of innovation by Biodesign. 
 Therefore, in this research, a hypothesis that "Companies founded after the 
Biodesign Program show high management performance from other start-up 
companies in the medical device area" was made, and it aims to discuss the quantify 
of innovation from the viewpoint of venture finance. If the program innovation is of 
relatively high quality, the success factors will be considered. If innovation is low 
quality, how to improve the problem will be considered. This educational program is 
attracting great attention also from the domestic medical device industry. This is 
because the Japanese medical device market share is largely separated in the United 
States, in addition it has the possibility to build Silicon Valley business ecosystem in 
Japan which could not imitate until now. The Japan Biodesign Program was launched 
in 2015, and entrepreneurship is being promoted by program participants.  
Furthermore, even in large corporations such as Terumo Corporation and small and 
medium-sized enterprises with 1000 or fewer employees, programs are being 
introduced internally and creating new businesses. Under such circumstances, 
reviewing the power to create the innovation of the program in detail and discussing 
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issues can be expected to make a big contribution to the revitalization of innovation 
in medical device industry and the development of the industry in Japan.   
14 
 
CHAPTER3． STANFORD BIODESIGN PROGRAM 
 
SECTION1. THE OVERVIEW 
  In 2001, Dr. Paul Yock leading the Medical Device Network faculty group in 
Stanford university founded the Stanford biodesign program as part of ‘Bio -X’, which 
was the Stanford's biosciences institute, bringing together biomedical and life science 
researchers, clinicians, engineers, physicists, and computational scientists to 
elucidate the secrets of the human body (In this case, the ‘X’ means the design of 
biomedical technologies). It is a program as a human resource development program 
to lead medical device innovation based on design thinking, featuring the approach 
to realize innovation by examining the viewpoint of commercialization from the early 
stage of development while developing the solution to the problem starting from the 
needs of the medical site. 
  Currently it is introduced in India, Singapore, Ireland, the UK, and Japan; 
furthermore it is being considered for introduction around the world including China 
and Brazil. In Japan, in order to introduce the Japan Biodesign Program, the 
University of Tokyo, Tohoku University, and Osaka University sign with the Stanford 
University with a program development partnership. Education and support for 
diverse human resources are being carried out with contents similar to those in the 
United States, and actual results have already been established by several companies 
from the Japan Biodesign Program. 
 
SECTION2. FELLOWSHIP 
  Fellowship is about a year course to learn the process of commercialization of 
medical device. Students will extract clinical needs from the medical field, and then 
learn commercialization skills. There are many excellent talents from all over the 
world, such as biosciences, engineering, computer science, product design, law, 
business, Ph.D., M.D., MBA qualification etc. However, in high competition, only 8 
people are elected each year, and the magnification is over 18 times. The Biodesign 
Program is based on the premise that it will proceed as a project with a diverse team.  
This is because bringing diversity to team members leads to high quality innovation 
creation. According to James March, “A well-balanced management of Exploration 
(knowledge exploration) and Exploitation (deepening of  knowledge) leads to 
innovation" 【 James March, 1991 】 The diversity of Biodesign's team members 
corresponds to Exploration, and the individual expertise of Biodesign's members 
corresponds to Exploitation. From this, it can be said that the Biodesign Program 
provides an environment in which excellent talent is likely to create innovation.  Also, 
in addition to knowledge and skills, the network where students can get is thought to 
greatly contribute to building the business ecosystem of the medical device industry. 
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SECTION3. THE PROCESS OF INNOVATING MEDICAL TECHNOLOGIES 
  Below are the results of the survey on the content of the Biodesign Program 
fellowship. The program is roughly divided into three phases (Identify, Invent, 
Implement), and each phase is further divided into two stages.  
 
 
 
 
 
1. Identify 
  The first stage in the Identify phase is "Needs finding". Biodesign Innovation 
Fellow firstly decides "Strategic focus" through discussion within the team. This 
represents the team's philosophy and direction, the scope of innovation expected, 
and aims to clarify "what you want to accomplish" and "how to influence our 
strengths and weaknesses". Also, when there are multiple choices, "judgment 
criteria" is necessary for choosing one that follows "Strategic focus". Determining 
the "Strategic focus" is very important for the Biodesign Program. Because 
Biodesign collects excellent talents with various industries, technologies and 
cultural backgrounds, conflicts will arise from differences in value criteria when 
making big decisions without advance direction determination. Subsequently, a 
need searches through "Clinical observation" is carried out. Actually goes to 
clinics, wards, operating rooms, intensive care rooms, etc. and extracts detailed 
needs existing on site by accompanying medical personnel for several months. 
The goal here is to find at least 200 clinical needs facing medical staff, patients, 
and other stakeholders. In order to make medical device in successful as a 
business, it is extremely important to extract the needs of the site clearly and 
embody it. Even if companies try to actually search for this type of need, they 
tend to develop technical viewpoints because they are difficult to observe on site 
for a long time. This program can be evaluated in that it is  beyond these hurdles 
and customer orientation is practiced. Finally, the clinical needs found here are 
Figure. Process of Biodesign program to create innovation.  
Source: http://www.jamti.or.jp/en/biodesign/program/ 
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organized and accumulated in a form that makes it easy to quantitatively 
evaluate “Needs statement (A way to X for Y in order to Z)". 
  The second is "Needs screening". In this step, the accumulated needs statement 
is scored and the task is narrowed down to about 4 according to the “Strategic 
focus” of the team. When scoring, a thorough investigation on existing treatment 
methods, epidemiology, markets, stakeholders etc. is required.  
2. Invent 
  In the Invent phase, the first is "concept generation". In this step, brainstorm 
the solution starting from the need statement narrowed down by needs 
screening. In doing so, 100 solutions will be created for one need statement 
based on guidance from experts at the University of Stanford Hasso Plattner 
Institute of Design (d, school).  
After brainstorming, it enters the stage of "Concept screening". In this stage, 
detailed investigation on prior patent, regulatory science, payment route, 
business model etc is carried out. In addition, it is important to consider the 
validity of the created solution idea. Also, in a laboratory established exclusively 
for the Biodesign Program, Fellow will prototype solutions and decide on the 
best development concepts by brushing up on them based on opinions from 
stakeholders. In addition, it is possible to minimize the risk of failure by 
prototyping at an early stage and repeatedly brushing up. 
3. Implement 
The first stage is "Strategy development". Fellow discusses specific intellectual 
property, regulation, clinical, quality, and redemption strategies and discusses 
risks in the realization of ideas. At the same time, through research and 
development, engineering and testing, they develop our own technology and 
consider realizing ideas. 
The end of Biodesign is the "Business planning" stage. At this stage, it is 
necessary to set up a practical business plan, to investigate fund procurement 
method and license strategy. Each team presents the output of the project to a 
group of experts representing the clinical, engineering, entrepreneurs, 
investment, and corporate sectors of the medical technology industry.  Then, 
based on feedback on it, they can choose their startup. 
 
SECTION4. OUTCOME 
 Biodesign students actually have many achievements. For example, more than 40 
companies have been born through the program, and it is known that there are 
several companies that have reached Exit. It can be asserted that this contributes to 
strengthening the business ecosystem in that it gathers talented people with little 
experience and created many experienced entrepreneurs. In addition to that, the 
evaluation is also high in terms of human resource career education, and there are 
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reports that 69% of the participants are in leadership positions. 
 According to James Wall et al., "More than 440,000 patients benefited from the 
technology developed directly from Biodesign Innovation Fellowship and more than 
1 million people were supported by solutions initiated by alumni after training."
【James Wall, 2016】Also on Stanford Biodesign's website, "800 million patients 
benefit directly from the technology developed by this program, more than 1 million 
people were supported by solutions created by alumni, plus , Established enterprises 
will have more than 600 regular employments "is stated. There is no doubt that 
program innovation can be created. 
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CHAPTER4． IMPACT ANALYSIS OF STANFORD BIODESIGN PROGRAM 
 Below, in order to verify the hypothesis of "Companies founded through the 
Biodesign Program show high management performance from other medical device 
startup companies", comparative analysis of the group of companies in both groups 
was conducted from the viewpoint of venture finance. 
 
SECTION1. SAMPLE SIZE 
1. Start-up company after Biodesign Program (Biodesign Start-ups) 
  From the list of companies listed on the Stanford Biodesign Program website, 
startup which is located around California was extracted. Among those 
companies, excluded those that do not exist on Crunchbase's database, 
companies that do not have Funding Amount information, Founder information, 
and companies that did not hold First Funding within five years after 
establishment. By this method, the total number of company data extracted was 
20 samples. (Furthermore, only from the above samples, companies excluded 
companies established after 2013 are excluded only when analyzing by setting 
Funding amount for 5 years as a dependent variable.  At this time, the total 
number of company data extracted was 14 companies. ) 
2. Start-up companies in the medical device industry (Medical Device Start-ups) 
  On the Crunchbase database, established in the medical device area (search 
category: Medical Device) after 2000, and with minimal regional bias compared 
to Biodesign Start-ups, the headquarter location extracted companies in 
California. Funding Status was limited to Seed, Early Stage Venture, Late Stage 
Venture, Private Equity, M&A, and IPO. Companies that do not have Funding 
Amount information, Founder information were excluded, and also companies 
that did not hold First Funding within five years after establishment were 
excluded. By this method, the extracted company data totaled 147 samples.  
(Incidentally, when analyzing by setting Funding amount for 5 years as a 
dependent variable, companies established after 2013 from the above sample 
were excluded. At this time, the total number of company data extracted was 105 
companies.) 
 
SECTION2. EXTRACTED DATA 
 For the above sample companies, the year of establishment, the first fundraising 
year, First Funding Amount (FFA)、Period till First Investment (PFI)、Funding amount 
for 5 years (FA5Y), Exit status, Number of Founders(NF) have extracted. In addition, 
whether there are women (Female), serial entrepreneurs (S.E.), Ph.D., MBA, M.D., 
famous university graduates (Edu; Harvard University, Yale University, Pennsylvania 
University, Princeton University, Columbia University, Brown University, Dirt Math 
University, Cornell University, Stanford University, MIT), people who has 
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Employment experience (E.E.), Managerial experience (M.E.), Medical practical 
experience (M.P.E.) have extracted. In extracting data, company information was used 
from Crunchbase, but on founder information was used from Crunchbase or 
LinkedIn. For selection criteria of famous universities, refer to articles by Tucker J. 
Marion. 【Tucker J. Marion, 2016】  
 
SECTION3. CHARACTERISTIC ANALYSIS 
 In this section, analysis was conducted for Biodesign Start-ups (20 companies) and 
Medical Device Start-ups (147 companies). 
1. Company information 
 
 
 
  For each sample company extracted, plotted number of new venture 
companies in each year is shown in the graph above. Given the fact that the 
start-up rate in the US is decreasing over the long term【Census Bureau, U. S., 
2013】, it is a specific point in this industry that the number of founders is 
increasing as a whole. However, the number of new venture companies has 
drastically decreased in several years. Specifically, it is 2002, 2010, 2015, and so 
on. Fund financing to start-up companies, etc. will be greatly affected by the 
economy, but considering that the medical device industry is unlikely to suffer 
the wave of economic fluctuations, it can be assumed that there is  an influence of 
economic fluctuations a little behind other industry. Therefore, it can be said that 
in 2002, stagnation of market activity due to the terrorist attacks in 2001, in 2010, 
Figure. Number of new venture companies in medical device industry.  
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the global financial and economic crisis of 2008 to 2009,  in 2015, the economic 
slowdown caused by the decline in crude oil prices in the second half of 2014 is 
affected. In the future, however, the number of start-up companies in the 
medical device industry will increase, as the recovery of the economy and 
changes to the aging society is expected to attract the medical device industry.   
  Looking at Biodesign Start-ups only, in the early years of the program 
founding in 2000-2005 it was founded only one company in six years. However, 
after 2006, it is not influenced by the wave of the economy, and there is almost 
one company founded almost every year. Considering that the Biodesign 
Program is 8 fellowships in a year, it can be said that this is a tremendous 
achievement. 
2. Funding status 
  The number of companies that succeeded in financing the first time after 
establishment in each year is shown in the graph below. As shown in the 
previous section, the Biodesign Start-ups found few noticeable funds in the first 
half of the graph because of its small number of founders in 2000-2005. However, 
from 2010 onwards, companies that succeed in raising the first fundraising will 
appear on a continuous basis, showing a trend similar to that of medical device 
startup companies. In 2014, there was a peak in the number of successful 
first-time financing. 
 
 
 Figure. Number of first funding in medical device industry.  
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 A graph of the total funding amount of companies that succeeded in financing 
the first time after the establishment is shown below. According to the graph, 
since there are positive peaks in 2003, 2007, 2011 and 2014, it can be said that the 
inflow of funds to new startup companies in the medical device industry was 
high in these years.  
 
 
 
 
 
Figure. Total amount of first funding in medical device industry.  
Figure. Average of first funding amount in medical device industry.  
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  However, looking at the graph showing the average amount of funds raised 
per company that succeeded in raising the first funding after the establishment 
in each year, there are no major changes in the year except 2003. In other words, 
although the total amount of funds raised for these years (except 2003) has 
increased, it cannot be said that a large venture with strong fund-raising ability 
appeared. Many excellent ventures appeared, and the background of the 
attention of the medical device industry overlapped with the inflow of funds to 
medical device ventures. In addition, the amount of funds raised per company is 
markedly high only in 2003, looking at the breakdown of these companies, 75% 
have reached Exit. At the time of the first fundraising, these companies were able 
to build a highly reliable company that can raise a large amount of funds, or it is 
assumed that a developed product at a high level could be trial-manufactured. In 
other words, it can be said that they had not needed funds up until this point, 
but had grown up with our own funds alone. As you can see from the fact that 
the number of start-ups of medical device start-up companies is small around 
2000 and the first fundraising has not taken place in 2000 and 2001,  at that time, 
there was little inflow of funds to medical device ventures, and as a result, it 
could be said that it was a harsh environment where only companies that can 
start up with self-financing can enter.  
3. Founding member status 
  The number distribution of founding members is shown in the following pie 
chart. Looking at this, it turns out that Medical Device Start-ups tends to have 
more people at the time of establishment. In particular, the proportion of 
companies founded by three people was more than twice that of Medical Device 
Start-ups compared to Biodesign Start-ups.  
 
  
 
 
Figure. The number of founding members in medical device industry. 
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  The status of the founding member is shown in the following graph.  The 
vertical axis is the percentage of firms that have talented personnel in the 
founding members among all company samples.  
  First of all, there was a difference in the proportion of companies that have 
serial entrepreneurs as founding members, while serial entrepreneurs were 
enrolled in 40.1% of corporate founding members in Medical Device Start-ups, 
while 30.0% in Biodesign Start-ups. From this, In Medical Device Start-ups, 
people with entrepreneurial experience belonging to the talent pool of business 
ecosystem are re-established, whereas in Biodesign Start-ups it is suggested that 
talented people who have no entrepreneurial experience are trying the company 
with the program as opportunity.  Furthermore, comparing the past entrance 
times of serial entrepreneurs in the founding members, Medical Device Start-ups 
(1.75 times) exceeds Biodesign Start-ups (1.50 times).  This also suggests that 
the skill of the start-up process in the founding team of Medical Device Start-ups 
is higher than that of Biodesign Start-ups.  
 
 
 
 
  Next, Biodesign Start-ups (30.0%) surpassed Medical Device Start-ups (18.7%) 
as a percentage of companies that have women in their founding members.  
Because this is also a member composition after selection as a program, 
consideration is given to incorporate women in the team members intentionally. 
Team formation of Biodesign Program is valid. Because, according to the article 
by Tucker J. Marion, "The performance of a company with at least one woman in 
Figure. Characteristic of founding members in medical device industry. 
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its foundation team is significantly higher than a company that is not so"【Tucker 
J. Marion, 2016】   
  The past education of founding members was analyzed. It was judged that 
there is no big difference in the ratio of Ph.D. and MBA. However, there was a 
big difference in the proportion of companies with at least one member of M.D. 
in the founding member, which was 27.2% in the Medical Device Start-ups and 
45.0% in the Biodesign Start-ups. In Biodesign Start-ups, it is inferred that this is 
an intentional organization for maintaining diversity in the program team.  As 
M.D. who are actually in the position to use medical device engage in innovation 
creation, it is thought that the possibility of offering products that have 
accurately dedicated customer needs to the world will increase.  At the graduate 
university, Biodesign Start-ups (80.0%) greatly exceeded Medical Device 
Start-ups (27.2%). This is probably because the Biodesign Program is being held 
at Stanford University and the program has many students of the university.  
  Finally, the work experience in companies before entrepreneurship was 
analyzed. Biodesign Start-ups (80.0%) greatly exceeded Medical Device Start-ups 
(54.4%) for the percentage of companies with at least one who has employment 
experience in the founding member. In addition, Medical Device Start-ups 
(46.2%) greatly exceeded Biodesign Start-ups (20.0%) for the percentage of 
companies with at least one who has managerial experience in the founding 
member. From this, it can be inferred that there are many young people who 
have few social experience in the Biodesign Start-ups founding members. In 
addition, Biodesign Start-ups (30.0%) greatly exceeded the Medical Device 
Start-ups (2.72%) of companies with at least one employee who has medical 
practical experience in the founding member.  From this analysis result, it was 
implied that the intentional organization of teams with attractiveness, awareness, 
diversity of the Biodesign Program invited this result.  Furthermore, as the low 
percentage of medical practical experience in Medical Device Start-ups, even if 
medical professionals excluding doctors have clinical needs at the work site, 
they have not been able to take the means of entrepreneurship.  And the problem 
has been solved by the Biodesign Program. 
 
SECTION4. QUANTITATIVE ANALYSIS 
1. Data and method 
 Below, in order to clarify how the Biodesign affects the initial success 
measurements of the startup company against the hypothesis of “Biodesign Start-ups 
show high management performance from Medical Device Start-ups ", it is verified 
using multiple regression analysis. 
 The data was mainly modified for statistical analysis from the data extracted in 
Chapter 4 - Section 2, and dependent and independent variables were set as follows. 
25 
 
At this time, continuous variables were normalized by taking natural logarithms.  At 
the time of statistical analysis, primary screening was carried out and those with high 
collinearity were excluded. 
 Dependent variable 
 First Funding Amount (FFA), Period till First Investment (PFI), Funding 
amount for 5 years (FA5Y), Presence of IPO (IPO), Presence of M&A (M&A). 
 Independent variable 
 (A) Dependent variable is set as First Funding Amount (FFA) 
  Independent variables are Period till first investment (PFI), Number of 
Founders (NF), The first funding year (Funded 20**_dummy), At least one 
female (Female_ dummy), At least one serial entrepreneur (S.E._dummy), At 
least one Ph.D. (Ph.D._dummy), At least one MBA (MBA_dummy), At least 
one M.D. (M.D._dummy), At least one graduates from famous university 
(Edu_dummy), At least one person who has employment experienced (E. 
E._dummy), At least one person who has managerial experience 
(M.E._dummy), At least person who has medical practical experience 
(M.P.E._dummy), Biodesign Start-ups (Biodesign_dummy), Biodesign×S.E.、
Biodesign×Female, Biodesign×Ph.D., Biodesign×MBA, Biodesign×M.D.,  
Biodesign×Edu, Biodesign×E.E., Biodesign×M.E., Biodesign×M.P.E., 
Female×S.E., Ph.D.×S.E., MBA×S.E., M.D.×S.E., Edu×S.E., E.E.×S.E. , 
M.E.×S.E. 、 M.P.E.×S.E., MBA×M.D., Ph.D.× M.D., MBA×Ph.D., 
Ph.D.×MBA×M.D. 
 At this time, the first funding year (Funding20 **_dummy) uses only 2003, 
2007, 2012, 2014 and 2016 which showed characteristic behavior.  
 (B) Dependent variable is set as Period till First Investment (PFI) 
  For the independent variable, First Funding Amount (FFA) was added, 
excluding Period till first investment (PFI) from the explanatory variable of 
(A) above. 
 (C) Dependent variable is set as Funding amount for 5 years (FA5Y) 
  The independent variable was obtained by adding First Funding Amount 
(FFA) to the explanatory variable of (A) above. (Excluded companies 
founded after 2013 from sample companies.)  
 (D) Dependent variable is set as Presence of IPO (IPO)、Presence of 
M&A(M&A) 
  The independent variable was obtained by adding First Funding Amount 
(FFA) to the explanatory variable of (A) above. 
2. Result of analysis 
 The correlation matrix of all the variables and the multiple regression analysis 
results are shown in the following table. 
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 Dependent variable is FFA, PFI, or FA5Y. 
  First, I would like to discuss the relationship between FFA, PFI and FA5Y. FFA 
and PFI are mutually complementary, and PFI is positively statistically 
significant for FFA. In other words, if it takes time to procure funds for the first 
time, the initial procurement amount tends to increase.  Regarding the period 
until the initial funding, there is no definite answer. The optimal strategy will 
change depending on the target industry, product characteristics, background of 
the founder. Improvement of product development, improvement of corporate 
credibility, early expansion of market share, shortening the period until next 
funding, and raising the procurement amount through corporate value 
improvement can be considered as merit of early successful financing. Early 
financing in the medical device industry is expected to improve corporate value 
by accelerating initial research and development of products. However, 
considering the dilution of the shares owned by the management team, it is not 
possible to procure funds in a short period of time, so it is necessary for 
individual companies to consider it. Looking at the relationship with FA5Y, it is 
clear that both FFA and PFI are statistically significant. It can be said that the 
period until initial funding is short and the large amount of funds has a strong 
influences on medium-term corporate growth. 
  Consider dummy variables that show the characteristics of the foundation 
team. As mentioned above, in the past research, it has been found that the 
performance of a company with at least one woman in its founding team is 
statistically showed positive performance compared with the other company. 
Also in this analysis, Female_dummy statistically showed positive effects for 
FFA. However, statistically significant effects were not seen for PFI and FA5Y. 
Although it was expected that management efficiency be improved by having at 
least one serial entrepreneur within the foundation team, S.E._dummy did not 
statistically show significant effect for any of the success indicators. It was 
expected that if the founding member received advanced education in the past it 
would have a positive influence on the success measurements. However, 
Edu_dummy just statistically showed positive effect for FA5Y, but otherwise had 
no positive effect. Ph.D._dummy, M.D._dummy tended to make PFI longer. 
  The dummy variable on the past employment experience of the foundation 
team was considered. For FFA, E.E._dummy statistically showed negative and 
M.E._dummy statistically showed positive. M.E._dummy statistically showed 
negative effect for PFI and M.P.E._dummy statistically showed positive for FA5Y. 
Resulting in a negative impact on early financing by employees. However, since 
it does not take into consideration years of employee experience and age factor, 
more detailed examination is necessary. Regarding the fact that managers 
experienced positive influences, there is a possibility that the management of the 
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foundation team worked positive. Entrepreneurship by experienced workers in 
the medical field has a positive influence on the medium term success.  This is 
expected to lead to the discovery of clear customer needs by experiences of 
actually working on the field as a position to use medical device.  
 
 
 
 
  Next, the cases where there were members with different advanced education 
within the foundation team were examined in detail.  There was no statistically 
Dependent Variable FFA PFI FA5Y
Independent Variable β t-ratio β t-ratio β t-ratio
FFA 0.228 2.625** 0.389 4.809***
PFI 0.219 2.625** -0.211 -2.676***
Funded2003_dummy 0.183 2.221* -0.11 -1.301
Funded2007_dummy 0.031 0.364 -0.156 -1.800*
Funded2012_dummy -0.108 -1.347 -0.106 -1.292
Funded2014_dummy -0.07 -0.844 0.134 1.593
Funded2016_dummy -0.308 -3.893*** -0.045 -0.53
NF -0.025 -0.282 0.053 0.6 -0.094 -1.034
Female_dummy 0.264 2.235** -0.084 -0.685 -0.03 -0.267
S.E._dummy 0.138 0.93 -0.018 -0.122 -0.188 -1.337
Ph.D._dummy -0.113 -0.864 0.239 1.817* -0.008 -0.068
MBA_dummy -0.114 -0.823 0.213 1.514 -0.045 -0.347
M.D._dummy -0.101 -0.668 0.275 1.804* -0.181 -1.263
Edu_dummy -0.066 -0.553 0.062 0.507 0.204 1.753*
E.E._dummy -0.207 -1.915* 0.102 0.915 0.009 0.083
M.E._dummy 0.381 3.380*** -0.226 -1.918* -0.165 -1.396
M.P.E._dummy -0.12 -0.981 0.097 0.774 0.27 2.310**
MBA×M.D. 0.061 0.425 -0.199 -1.369 0.302 2.235**
PhD×M.D. 0.217 1.557 -0.465 -3.387*** -0.256 -2.046**
MBA×Ph.D. -0.053 -0.382 -0.204 -1.452 0.125 0.907
Ph.D.×M.D.×MBA -0.006 -0.033 0.547 2.990*** -0.168 -0.897
Biodesign_dummy -0.058 -0.399 0.225 1.531 -0.267 -2.120**
Biodesign×S.E. 0.039 0.346 -0.02 -0.174 -0.323 -3.043***
Biodesign×Female 0.073 0.613 -0.169 -1.399 -0.424 -3.627***
Biodesign×Ph.D. -0.027 -0.266 -0.136 -1.308 0.262 2.321**
Biodesign×MBA -0.139 -1.309 0.116 1.076
Biodesign×M.D. 0.093 0.55 -0.287 -1.681* 0.398 2.400**
Biodesign×Edu
Biodesign×E.E.
Biodesign×M.E. 0.015 0.153 0.046 0.454 0.004 0.041
Biodesign×M.P.E. 0.051 0.286 0.12 0.662 -0.249 -1.445
Female×S.E. -0.339 -3.001*** 0.26 2.231** 0.076 0.72
Ph.D.×S.E. 0.034 0.287 -0.045 -0.371 -0.09 -0.766
MBA×S.E. 0.241 1.790* -0.054 -0.389 0.083 0.653
M.D.×S.E. -0.102 -0.746 -0.019 -0.134 0.654 4.644***
Edu×S.E. 0.123 0.97 -0.071 -0.552 -0.572 -4.407***
E.E.×S.E. 0.141 0.919 -0.181 -1.167 0.115 0.843
M.E.×S.E.
M.P.E.×S.E. -0.394 -2.785*** -0.007 -0.044 0.187 1.372
( a constant) 39.446 -1.003 0.938
p-value  *(p<0.1), **(p<0.05), ***(p<0.01)
Figure. Results of the multiple regression analysis.  
(Dependent variable is FFA, PFI, or FA5Y.) 
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significant variable for FFA. For PFI, Ph.D.×M.D. statistically showed negative 
effect, and Ph.D.×M.D.×MBA statistically showed positive effect. Also, for FA5Y, 
MBA×M.D. statistically showed positive effect, and Ph.D.×M.D. statistically 
showed negative effect. 
  I would like to discuss whether Biodesign Start-ups will affect 
short-medium-term success indicators. Regarding Biodesign_dummy, 
statistically significant effects did not appear in this analysis in FFA, PFI which 
can be said as an initial success indicator. However, in FA5Y which can be said as 
a medium-term success indicator, it statistically showed negative effect. From 
this result, Biodesign Start-ups and Medical Device Start-ups are nearly equal in 
quality and expectation of companies at the time of establishment. However, it 
can be said that the performance in the medium term is low. In Biodesign, a 
business development support mentor registered supports the creation of 
product ideas, high level business plans, and leads excellent and diverse 
members from idea creation to founding. Therefore, there is a possibility that the 
founding member may have complemented the fewer number of serial 
entrepreneurs. This is one reason why it is possible to obtain the same evaluation 
as a Medical Device Start-ups in the short term. However, there is a possibility 
that support has not been delivered in the medium term management, and it can 
be said as a future task as a program. 
  The relationship between the Biodesign Program and the characteristics of the 
foundation team was examined in more detail. First, in Biodesign×S.E., it 
statistically showed negative effect for FA5Y. Also, when looking at 
Biodesign×Female, it is not statistically significant for FFA but statistically 
showed negative effect for FA5Y. Compared to the fact that Female_dummy is 
statistically showed positive effect with respect to FFA and no statistical 
significance was seen for FA5Y, it can be seen that the Biodesign Program does 
not take advantage of the merits of women being in the foundation team. 
However, Biodesign Start-ups has many women in their founding teams 
compared with Medical Device Start-ups, and the number of samples is small. In 
the long run it cannot be denied that this shows a significant  value as a success 
factor of Biodesign Start-ups.  In other respects, it is characteristic that 
Biodesign×Ph.D., Biodesign×M.D. is statistically showed positive effect for FA5Y. 
Further to Biodesign×M.D., It statistically showed negative effect for PFI, which 
shows that it works to shorten the procurement period. Considering that 
Ph.D._dummy and M.D._dummy is not statistically significant for FA5Y, it is 
thought that the Biodesign Program can smoothly transition to enterprise 
growth by linking the technical and medical capabilities of Ph.D., M.D. with 
commercialization. Here, the strength of the Biodesign program is emerging.  
Considering that Biodesign_dummy statistically showed negative effect with 
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respect to FA5Y, other factors may make the overall evaluation of the Biodesign 
Program lower. 
 
 
 
Figure. Results of the multiple regression analysis.  
(Dependent variable is IPO or M&A.) 
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  Finally, the influence of serial entrepreneurs' founding members on success 
measurements was examined in greater detail. Female×S.E. statistically showed 
negative effect for FFA and statistically showed positive effect for PFI. MBA×S.E. 
statistically showed positive effect for FFA. The most characteristic point is that 
M.D.×S.E. Is just positive statistical significance, however, Edu×S.E. is negatively 
statistically superior to FA5Y. As S.E._dummy and M.D._dummy did not show 
statistical significance, it can be presumed that a serial entrepreneur could make 
M.D. experience and skills available for business application.  Also, despite 
relatively few serial entrepreneurs in Biodesign Start-ups, M.D.×S.E. companies 
(15.0%) are more than Medical Device Start-ups (11.6%). This is due to the high 
M.D. ratio in Biodesign Start-ups, suggesting that the Biodesign Program has the 
potential to achieve high outcomes in the long run. M.D.×S.E. also has a strong 
influence on the success measurements even when compared with MBA×M.D. 
and Biodesign×M.D. However, M.P.E.×S.E. statistically showed negative effect 
for FFA. 
 Dependent variable is IPO or M&A. 
  With the exit from IPO as a success index, Edu_dummy, E.E.×S.E. statistically 
showed positive effect, and E.E._dummy statistically showed negative effect. 
Using Exit by M&A as a success measurement, S.E._dummy statistically showed 
positive effect, and M.E._dummy, Edu×S.E. statistically showed negative effect. 
No influence of Biodesign Program was seen with regard to these success 
measurement. The reason for this is that several exited Biodesign Start-ups are 
excluded in the Crunchbase for samples this time. From now on, it can be said 
that detailed investigation is required for more samples.   
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CHAPTER5． CONCLUSION 
 
 In this paper, the management performance of companies established after the 
"Biodesign Program" from the Stanford University got investigated using the public 
data to verify the hypothesis "Biodesign Start-ups show high management 
performance from Medical Device Start-ups ". 
 According to the survey, the Biodesign Program has shown that comprehensive 
support is being given to teams with diversity and expertise in each of idea creation 
stage, product development stage, and commercialization stage. At the idea creation 
stage, thorough clinical needs extraction was done at the medical scene contracted 
with the Biodesign Program. At the product development stage, Fellows are trying to 
embody the solution to clinical needs, with the cooperation of Hasso Plattner 
Institute of Design (d, school) of Stanford University. At the commercialization stage, 
support is also provided for professional entrepreneurs to prepare business plans, 
regulatory compliance strategies, and network formation. From these facts, it was 
speculated that in the Biodesign Program, an environment in which innovation is 
more efficiently born is being developed. Indeed, more than 40 companies have been 
born from the Biodesign Program, and more than 800,000 patients benefit from the 
worldwide. 
 An analysis of the founding team of Biodesign Start-ups showed that the 
proportion of serial entrepreneurs was relatively small.  From here, it is shown that 
the Biodesign Program is contributing to strengthening the business ecosystem in the 
medical device industry by involving talented people who have no entrepreneurial 
experience. Compared to Medical Device Start-ups, Biodesign Start-ups has a high 
diversity, with women, M.D., famous university graduates, experienced workers, 
experienced medical workers, etc. enrolled in the founding team at a high rate.  As 
diversity is always told as one of the factors causing innovation, the team 
composition of the Biodesign Program is considered to be suitable for innovation.  
 From the quantitative analysis of the management performance using the amount 
of funds raised as a success measurement, Biodesign Start-ups showed almost the 
same results as the Medical Device Start-ups for short-term funding. However, it 
statistically showed negative performance in the medium term funding total. But, 
when examined in more detail, it became clear that Biodesign Start-ups that Ph.D., 
M.D. is enrolled showed significantly positive performance against medium-term 
capital gains.  Considering that Ph.D., M.D. alone was not statistically significant for 
medium-term funding, it was suggested that by combining Ph.D., M.D.'s expertise 
and medical ability with commercialization with the support of the Biodesign 
Program, it affected management performance improvement. The fact that M.D. on 
the same founding team as Serial Entrepreneur had a positive influence on 
management performance was also found. Therefore, it was thought that combining 
34 
 
the elements of business into medical-engineering collaboration successfully brings 
out the merit of the Biodesign Program. In the analysis using the Exit status as a 
success index, the impact of the Biodesign Program was not seen. 
  Based on the results of this study, I would like to mention two points to note in 
introducing Biodesign in Japan. First of all, it is about human resources selection at 
the time of program operation. Based on the statistical analysis results, it was found 
that Biodesign is good at extending the ability as an entrepreneur from highly skilled 
human resources such as Ph.D., M.D. Therefore, at the time of selection of the 
program participants, it can be said that an environment should be established to 
actively appoint these experts. It is also well known that Ph.D. holders in Japan are 
fewer than those in other countries. Therefore, it should be promoted to increase the 
number of Ph.D. holders in Japan, or to construct a mechanism to accept foreign Ph.D. 
holders. Alternatively, it may be one of the measures to give preferential treatment to 
researchers at the level equivalent to Ph.D. belonging to a large Japanese company to 
the Biodesign program. When operating Biodesign in the form of enterprise 
introduction, it is relatively easy to use research findings inside the company, so here 
it will be recognized as another issue how to involve M.D. inside the company. 
Through these measures, the probability of innovative creation when operating the 
Biodesign program in Japan is expected to improve. 
 The second point is how to socialize the startup company born based on innovative 
ideas. In the United States, companies founded after the Biodesign Program showed 
significantly negative management performance in the medium term although they 
were not significant in the short term compared with startup companies in other 
medical device areas. If the same situation will occur in when Biodesign is 
introduced in Japan, as investors like venture capital are not substantial, even if 
business ideas like Silicon Valley are born, early financing will be as difficult as ever 
due to environmental factors. In addition to considering measures to increase risk 
money supply volume in Japan, acceptance of overseas risk money, and promotion of 
incubation business for start-up companies by small and medium enterprises will 
become necessary. Also, if you aim to create innovation within your company using 
Biodesign, discussions on how to make use of innovator motivation will become 
necessary. 
 As the limit of this paper, since it is only Crunchbase information in corporate data 
extraction, it cannot be said that it is comprehensive. Statistical analysis using 
multiple databases will be necessary to conduct more detailed studies.  Also, one 
more thing is the analysis in this study is only about Stanford Biodesign not 
analyzing India, Singapore, Ireland, the UK, and Japan. In the future, analyzation 
and comparison about country-specific performance and mechanism will be needed. 
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